RADIN Health and AZmed have expanded their strategic partnership following AZmed’s third US FDA clearance for the Rayvolve AI Suite’s AZtrauma module, broadening its capabilities for X-ray analysis and triage.

The expanded clearance extends AZtrauma beyond fracture detection to include joint effusions and dislocations across adult and paediatric populations aged two years and above. The development addresses a growing operational challenge in radiology, where rising imaging volumes, workforce pressure and reporting backlogs continue to affect diagnostic workflows.

AZtrauma is positioned as an AI-supported triage tool that can identify fractures, joint effusions and dislocations before the radiologist opens the study. According to the companies, this makes it the only FDA-cleared AI solution in the United States covering all three pathology categories on X-rays.

The clearance follows the publication of the Cohen et al. 2026 study, which validated the complete X-ray AI suite using 258,373 X-rays from 100 clinical centres across 26 countries and five continents. This scale of validation is relevant for radiology AI adoption, where generalisability across healthcare settings remains a key consideration.

Through the partnership, AZmed’s Rayvolve AI Suite modules, including AZtrauma and AZchest, are integrated into RADIN’s cloud-based platform. RADIN’s system combines RIS, PACS, Dictation AI and study orchestration, with AZmed’s structured reporting images and data feeding directly into RADIN PACS to support AI-driven reporting insights and reduce manual transfer risk.

RADIN’s platform also processes DICOM structured reports and uses AI OCR for handwritten notes, prescriptions and reports. Its AI-assisted dictation mode is reported to improve reporting speed by up to 70 percent compared with legacy dictation systems.